These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 8534930

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
    Tapiero H, Nguyen-Ba G, Lampidis TJ.
    Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
    [Abstract] [Full Text] [Related]

  • 3. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
    Watanabe M, Komeshima N, Naito M, Isoe T, Otake N, Tsuruo T.
    Cancer Res; 1991 Jan 01; 51(1):157-61. PubMed ID: 1988080
    [Abstract] [Full Text] [Related]

  • 4. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R.
    Oncol Res; 1996 Jan 01; 8(6):229-38. PubMed ID: 8895198
    [Abstract] [Full Text] [Related]

  • 5. Aclarubicin inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 murine leukemic cells.
    Nagata T, Higashigawa M, Shimono Y, Cao DC, Yan Mao X, M'soka T, Inamochi H, Hori H, Kawasaki H, Sakurai M.
    J Exp Clin Cancer Res; 1998 Dec 01; 17(4):435-42. PubMed ID: 10089064
    [Abstract] [Full Text] [Related]

  • 6. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.
    Deffie AM, Batra JK, Goldenberg GJ.
    Cancer Res; 1989 Jan 01; 49(1):58-62. PubMed ID: 2535693
    [Abstract] [Full Text] [Related]

  • 7. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
    De Isabella P, Capranico G, Binaschi M, Tinelli S, Zunino F.
    Mol Pharmacol; 1990 Jan 01; 37(1):11-6. PubMed ID: 2153905
    [Abstract] [Full Text] [Related]

  • 8. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S, Benchokroun Y, Larsen AK.
    Mol Pharmacol; 1995 May 01; 47(5):898-906. PubMed ID: 7746278
    [Abstract] [Full Text] [Related]

  • 9. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WD, Goldenberg GJ.
    Cancer Res; 1988 Jul 01; 48(13):3595-602. PubMed ID: 2897875
    [Abstract] [Full Text] [Related]

  • 10. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R, Grabowski D, Ford J, Heiss C, Kerrigan D, Pommier Y.
    Cancer Commun; 1989 Jul 01; 1(4):217-24. PubMed ID: 2576973
    [Abstract] [Full Text] [Related]

  • 11. Combined modalities of resistance in etoposide-resistant human KB cell lines.
    Ferguson PJ, Fisher MH, Stephenson J, Li DH, Zhou BS, Cheng YC.
    Cancer Res; 1988 Nov 01; 48(21):5956-64. PubMed ID: 2844393
    [Abstract] [Full Text] [Related]

  • 12. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
    Tsuruo T.
    Gan To Kagaku Ryoho; 1984 Mar 01; 11(3 Pt 2):750-9. PubMed ID: 6585181
    [Abstract] [Full Text] [Related]

  • 13. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA, Padmanabhan R, Hwang J, Gottesman MM, Pastan I.
    J Cell Physiol; 1993 May 01; 155(2):414-25. PubMed ID: 8097746
    [Abstract] [Full Text] [Related]

  • 14. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y.
    Cancer Res; 1989 Oct 15; 49(20):5537-42. PubMed ID: 2790778
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Acquired vs innate multidrug resistance and the effect of calcium channel blockers.
    Tsuruo T.
    Prog Clin Biol Res; 1986 Oct 15; 223():203-16. PubMed ID: 3468516
    [Abstract] [Full Text] [Related]

  • 17. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N.
    Cancer Res; 1989 Aug 01; 49(15):4098-102. PubMed ID: 2472873
    [Abstract] [Full Text] [Related]

  • 18. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
    Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Santi S, Ferracini R, Maraldi NM.
    Eur J Cell Biol; 1995 Nov 01; 68(3):226-39. PubMed ID: 8603675
    [Abstract] [Full Text] [Related]

  • 19. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
    Fukushima T, Takemura H, Yamashita T, Ishisaka T, Inai K, Imamura S, Urasaki Y, Ueda T.
    Anticancer Res; 1999 Nov 01; 19(6B):5111-5. PubMed ID: 10697518
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin.
    Hong WS, Jung HY, Yang SK, Kim HR, Min YI.
    Anticancer Res; 1997 Nov 01; 17(5A):3613-6. PubMed ID: 9413212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.